Oregon and Lantern collaborate to develop drug candidate for various cancer indications
Anticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024 Oregon Therapeutics…
Read MoreAnticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024 Oregon Therapeutics…
Read MoreGossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications Chiesi Group and Gossamer Bio have…
Read MoreThe findings could potentially lead to new therapies and could stop the growth of cancers Johns Hopkins Medicine…
Read MoreThe rare and fatal progressive neurodegenerative disease is estimated to affect 5,000 people in the UK The Francis…
Read MoreThe chronic brain disease that causes seizures currently affects around 600,000 people living in the UK The NHS…
Read MoreThe INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda A phase 3 international trial evaluating…
Read MoreNeurological disorders, such as epilepsy or chronic pain, affect over three billion people worldwide Researchers at the University…
Read MoreDespite ever increasing funding, clinical trials in primary biliary cholangitis (PBC) continue to struggle. PBC is an often…
Read MoreBacteroides fragilis in the gut improves immunity and immunotherapy treatment responses Researchers from the Francis Crick Institute, the…
Read MoreThe inherited disorder is caused by genetic mutations that affects haemoglobin production Nova Laboratories’ Xromi (hydroxycarbamide) has received…
Read More